<DOC>
	<DOC>NCT01266265</DOC>
	<brief_summary>A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies</brief_summary>
	<brief_title>Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies</brief_title>
	<detailed_description>A post marketing surveillance to determine the type and incidence of oro/nasopharyngeal or pulmonary adverse events that may occur in patients treated with commercially available Tyvaso®(treprostinil) Inhalation Solution. A comparison will be made to the type and incidence of events in patients receiving other FDA approved therapies for pulmonary arterial hypertension, as a control measure.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Clinical diagnosis of PAH, WHO GROUP I Prescribed and is currently receiving Tyvaso and/or other FDAapproved therapy for the treatment of PAH Willing and able to provide written informed consent Previous initiation and permanent discontinuation of Tyvaso Participation in an investigational clinical drug or device trial within 30 days of enrollment Current or past diagnosis of lung neoplasm Active gastrointestinal or pulmonary bleed at enrollment Planned surgical intervention for treatment of PAH e.g., atrial septostomy or transplant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>treprostinil sodium</keyword>
	<keyword>Tyvaso</keyword>
	<keyword>inhalation</keyword>
	<keyword>Ventavis</keyword>
	<keyword>iloprost</keyword>
	<keyword>prostacyclin</keyword>
	<keyword>epoprostenol sodium</keyword>
	<keyword>Flolan</keyword>
	<keyword>Veletri</keyword>
	<keyword>subcutaneous and intravenous prostacyclin analogue</keyword>
	<keyword>Remodulin</keyword>
	<keyword>oral ERA</keyword>
	<keyword>bosentan</keyword>
	<keyword>Tracleer</keyword>
	<keyword>ambrisentan</keyword>
	<keyword>Letairis</keyword>
	<keyword>oral PDE5 inhibitors</keyword>
	<keyword>sildenafil</keyword>
	<keyword>Revatio</keyword>
	<keyword>tadalafil</keyword>
	<keyword>Adcirca</keyword>
	<keyword>Opsumit</keyword>
	<keyword>macitentan</keyword>
	<keyword>Adempas</keyword>
	<keyword>riociguat</keyword>
	<keyword>Orenitram</keyword>
	<keyword>oral treprostinil</keyword>
</DOC>